Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Myelodysplastic Syndrome Red Blood Cell Physiology Abnormalities and Their Correlation with Disease Risk and Therapeutic Interventions

Pinelopi Vryttia, Konstantina Theocharaki, Eugenia Kazolia, Christina Apostolopoulou, Anthi Bouchla, Ioannis V Kostopoulos, Sotirios Papageorgiou, Georgia Tzafa, Ourania Tsitsilonis, Vasiliki Pappa, Marianna Antonelou

Blood (2023) 142 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2023-186143

Published: 2023

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Anthi Bouchla, Theodoros Loupis, Georgia Delikonstantinos, Frieda Kontsioti, Vassiliki Mpakou, Maria Dellatola, Maria Pagoni, Konstantinos Theodorakopoulos, Sotirios Papageorgiou, Argiris Symeonidis, Vassiliki Pappa

Blood (2022) 140 (Supplement 1): 6250–6251.

https://doi.org/10.1182/blood-2022-158980

Published: 2022

Journal Articles

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Christina-Nefeli Kontandreopoulou, Stavroula Syriopoulou, Panagiotis T Diamantopoulos, Nefeli Giannakopoulou, Dimitra Vlachopoulou, Panagiota Katsiampoura, Christos Stafylidis, Maria Dimou, Athanasios Galanopoulos, Sotirios Papageorgiou, Eleftheria Hatzimichael, Vassiliki Pappa, Kotsianidis Ioannis, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou

Blood (2022) 140 (Supplement 1): 6958–6959.

https://doi.org/10.1182/blood-2022-165870

Published: 2022

Journal Articles

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Blood (2021) 138 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2021-149630

Published: 2021

Journal Articles

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136940

Published: 2020

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Panagiotis T Diamantopoulos, MD PhD, Vassiliki Pappa, MD, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, Alexandra Kourakli, MD PhD, Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Elena E. Solomou, MD, Anastasia Pouli, MD PhD, Panagiotis Panagiotidis, MD PhD, Maria Dimou, MD PhD, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, MD MSc, Anna Vardi, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Georgia Kaiafa, MD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, PhD, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, MD PhD, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5427.

https://doi.org/10.1182/blood-2019-127417

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Frieda Kontsioti, PhD, Zoi Tsakiraki, MD, Sotirios Papageorgiou, MD PhD, Efthimia Mpazani, MD, Irene Glezou, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Athanasios Galanopoulos, MD PhD, Argiris Symeonidis, MD PhD, Nora-Athina Viniou, MD PhD, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, MD PhD, Periklis Foukas, MD PhD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5403.

https://doi.org/10.1182/blood-2019-122424

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, PhD, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, MD PhD, Evangelia Nakou, Anastasia Hadzidimitriou, PhD, George Kassiotis, Elli Papaemmanuil, PhD, Ioannis Mitroulis, Ioannis Kotsianidis

Blood (2019) 134 (Supplement_1): 2988.

https://doi.org/10.1182/blood-2019-126504

Published: 2019

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Nora Viniou, MD, Athanasios Galanopoulos, MD PhD, Kalliopi Zafeiropoulou, Kotsianidis Ioannis, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 3825.

https://doi.org/10.1182/blood.V130.Suppl_1.3825.3825

Published: 2017

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 4252.

https://doi.org/10.1182/blood.V130.Suppl_1.4252.4252

Published: 2017

Journal Articles

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 1693.

https://doi.org/10.1182/blood.V130.Suppl_1.1693.1693

Published: 2017

Journal Articles

Apoptosis Induction and Cell Cycle Profiling after Treatment with Low-Dose Decitabine and/or Bortezomib in the AML Cell Line Kasumi-1

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Athanassios Velentzas, PhD, Frieda Kontsioti, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 4994.

https://doi.org/10.1182/blood.V130.Suppl_1.4994.4994

Published: 2017

Journal Articles

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

Paraskevi Miltiades, Irene Bouchliou, Evangelia Nakou, Emmanuil Spanoudakis, Sotirios Papageorgiou, Vasiliki Pappa, Maria Papaioannou, Eleytherios Moustakidis, Sofia Vakalopoulou, Vasilia Garipidou, Konstantinos Tsatalas, Ioannis Kotsianidis

Blood (2010) 116 (21): 2921.

https://doi.org/10.1182/blood.V116.21.2921.2921

Published: 2010

NARROW

Myelodysplastic Syndrome Red Blood Cell Physiology Abnormalities and Their Correlation with Disease Risk and Therapeutic Interventions

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. A Retrospective Analysis of the Hellenic (Greek) Mds Study Group

Apoptosis Induction and Cell Cycle Profiling after Treatment with Low-Dose Decitabine and/or Bortezomib in the AML Cell Line Kasumi-1

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only